Coiffier B et al. Identification of patient subgroups demonstrating longer progression-free survival (PFS) benefit with bortezomib-rituximab versus rituximab in patients with relapsed or refractory follicular lymphoma (FL): Biomarker analyses of the Phase 3 LYM3001 study. Proc ASH 2011;Abstract 265.

Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division of the James P Wilmot Cancer Center at the University of Rochester in Rochester, New York.